Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis

Inclusion Criteria: * Adult patients (at least 18 years old) * Plasma HIV RNA \> 1000 copies/ml * HIV-1-infection confirmed by ELISA and Western blot or Immunofluorescence * ART naïve patients or * ART for less than 3 months and more than 6 months ago ; an HIV resistance genotype at baseline showing no mutation to NNRTI and TDF or 3TC will be required * For women of childbearing age, negative urinary test for pregnancy and to accept contraceptive methods: condom use and intra-uterine device when possible or declare no wish of pregnancy in the coming year. * Confirmed or probable TB * TB treatment including rifampin started since 2 to 8 weeks before randomisation * Signed informed consent form * For French patients, to be affiliated to the National Health Care System Exclusion Criteria: * HIV-2 infection (single or with HIV-1) * Woman who is pregnant or likely to become so, is breastfeeding or refuses to use contraception * ALT\>2.5N, Hb \<7g/dl, neutrophils \< 750/mm3, platelet\<50 000/mm3, bilirubin \>5N, lipase \>3N * Creatinine clearance \<60ml/min as assessed by the Cockcroft method * Ongoing psychiatric pathology or any condition (including, but not limited to, the consumption of alcohol or drugs) which might, in the investigator's opinion, compromise the safety of treatment and/or patient compliance with the protocol * Concomitant treatments including phenytoin or phenobarbital (compounds interacting with UGT1A1) * Prior TB with a Mycobacterium tuberculosis strain resistant to rifampin * TB treatment started for more than 8 weeks before randomisation